Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
Eis inhibitors
US10253035B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10253035-B2 |
| Application number | US-201715836666-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 8, 2017 |
| Priority date | Dec 8, 2016 |
| Publication date | Apr 9, 2019 |
| Grant date | Apr 9, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: wherein R 1 is selected from the group consisting of H, p-F, m,p-di-F; and R 2 is selected from the group consisting of H, o-F, m-F, m-Cl, m-Br, m-OH, m-OMe, p-F, p-Cl, p-Br, and p-Me. 2. A pharmaceutical composition comprising the compound of claim 1 , and a suitable pharmaceutical carrier. 3. A method of treating aminoglycoside-resistant Mycobacterium tuberculosis (Mtb), comprising administering an effective amount of the compound of claim 1 . 4. The method of claim 3 , and further comprising administering an aminoglycoside. 5. The method of claim 4 , wherein the aminoglycoside is kanamycin (KAN). 6. The method of claim 4 , wherein the aminoglycoside is administered to a subject in need of treatment for aminoglycoside-resistant Mtb. 7. A composition comprising the compound of claim 1 and an aminoglycoside. 8. The composition of claim 7 , wherein the aminoglycoside is kanamycin (KAN).
Assignees
Inventors
Classifications
with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring · CPC title
Seven-membered rings · CPC title
having an aryl radical as the second substituent in position 4 · CPC title
- C07D491/048Primary
the oxygen-containing ring being five-membered · CPC title
with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10253035B2 cover?
- Compounds and compositions are disclosed, which are useful as inhibitors of acetyltransferase Eis, a mediator of kanamycin resistance in Mycobacterium tuberculosis.
- Who is the assignee on this patent?
- Univ Kentucky Res Found
- What technology area does this patent fall under?
- Primary CPC classification C07D491/048. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).